683 Capital Management’s Ovid Therapeutics OVID Stock Holding History

683 Capital Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-42,088	Closed	-$175K	–	170
2019 Q4	$175K	Buy	+42,088	New	+$133K	0.02%	128

Other funds holding OVID

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

683 Capital Management's OVID Position: Q1 2020 in Review

683 Capital Management sold out of Ovid Therapeutics (OVID) in Q1 2020, closing a stake of 42,088 shares — an estimated $175K sold.

683 Capital Management first reported a position in OVID in Q4 2019 and held it in 1 quarter. The position peaked at $175K in Q4 2019. 57 funds tracked by Wall St. Rank hold OVID as of Q1 2020.

683 Capital Management reported no remaining Ovid Therapeutics position as of Q1 2020 after selling out during the quarter.
683 Capital Management sold 42,088 Ovid Therapeutics shares in Q1 2020, an estimated $175K.
683 Capital Management first reported a position in Ovid Therapeutics in Q4 2019 and held it in 1 quarter.
683 Capital Management's Ovid Therapeutics position peaked at $175K in Q4 2019.
57 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2020.

Based on 683 Capital Management's 13F filing for Q1 2020, filed 15 May 2020.